TP53 and Miyoshi myopathy: Previous clinical trials have demonstrated that bortezomib-based regimens are effective in the treatment of MM and are able to overcome the unfavorable effect of several abnormalities [del (13q), t(4;14), t(14;16), del (p53) and 1q21 gain] (31–35).